Unsafe
Noncompliant
Patient Risk:
High
Summary
Major portions of the extracted claims (pricing, patent/protection status, specific generic manufacturers, and generic substitution/bioequivalence/cost narratives) are not supported by the provided label text. Several side-effect claims are asserted as common without label support, and one side-effect description is not supported.
Category Scores
Accurate Statements
Silodosin is an alpha-1 blocker.
Supported by label: 11 DESCRIPTION; 12.1 Mechanism of Action.
Silodosin works by relaxing the muscles in the prostate and bladder neck.
Supported by label: 12.1 Mechanism of Action.
The relaxation produced by Silodosin improves urine flow.
Supported by label: 12.1 Mechanism of Action.
Silodosin reduces symptoms of benign prostatic hyperplasia (BPH), including difficulty urinating, weak stream, and frequent urination.
Supported by label: 1 INDICATIONS AND USAGE; 12.1 Mechanism of Action; 14.1 Benign Prostatic Hyperplasia.
Silodosin is a prescription medication.
Supported by label: 17 PATIENT COUNSELING INFORMATION (Rx only).
Silodosin should only be taken under the guidance of a healthcare professional after a diagnosis of benign prostatic hyperplasia.
Partially supported by label: 1 INDICATIONS AND USAGE; 17 PATIENT COUNSELING INFORMATION (counseling/indication context).
Common side effects of Silodosin include dizziness.
Partially supported by label: 17 PATIENT COUNSELING INFORMATION (postural hypotension symptoms such as dizziness).
Common side effects of Silodosin include retrograde ejaculation.
Partially supported by label: 17 PATIENT COUNSELING INFORMATION (reduced/no semen with orgasm).
Unsupported Statements
The price of generic Silodosin 8 mg can vary based on manufacturer, dosage, quantity, and pharmacy.
No pricing/manufacturer/market availability or cost information is present in the provided label sections.
A 30-day supply of generic Silodosin 8 mg typically ranges from $15 to $35.
No pricing/range information is present in the provided label sections.
Patent protection for Silodosin has largely expired in major markets.
No patent/protection status information is present in the provided label sections.
The expiration of Silodosin patent protection allows for the production and sale of generic versions.
No patent/protection or generic-authorization rationale is present in the provided label sections.
Several pharmaceutical companies produce generic versions of Silodosin.
No information about generic manufacturers is present in the provided label sections.
Teva Pharmaceuticals produces generic versions of Silodosin.
No information about specific generic manufacturers is present in the provided label sections.
Mylan N.V. (now Viatris) produces generic versions of Silodosin.
No information about specific generic manufacturers is present in the provided label sections.
Aurobindo Pharma produces generic versions of Silodosin.
No information about specific generic manufacturers is present in the provided label sections.
Common side effects of Silodosin include headache.
No headache adverse effect claim is present in the provided label sections.
Common side effects of Silodosin include diarrhea.
No diarrhea adverse effect claim is present in the provided label sections.
Common side effects of Silodosin include nausea.
No nausea adverse effect claim is present in the provided label sections.
Retrograde ejaculation is a side effect where semen enters the bladder during orgasm.
The provided label does not define retrograde ejaculation in this way; it only describes orgasm with reduced or no semen (17).
Generic Silodosin contains the same active ingredient as the brand-name drug.
The provided label sections do not discuss generic substitution or active-ingredient equivalence.
Generic Silodosin is bioequivalent to the brand-name drug.
The provided label sections do not discuss bioequivalence for generics.
Because generic Silodosin is bioequivalent, it is expected to have the same therapeutic effect and safety profile as the brand-name drug.
The provided label sections do not discuss bioequivalence-based expectations for generics.
The primary difference between generic and brand-name Silodosin is typically the cost.
No comparison narrative between brand and generic (including cost as primary difference) is present in the provided label sections.
Generic Silodosin is more affordable than brand-name Silodosin.
No affordability/cost comparison information is present in the provided label sections.
Contradictions
Important Omissions
If the intent was to describe clinical use details, the provided label excerpts do not include dosage/administration instructions beyond patient counseling (e.g., taking once daily with a meal), nor do they include the full Warnings/Precautions or Adverse Reactions sections. The extracted claims do not attempt to cite or reflect label-specific warnings/contraindications beyond the partial counseling statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple adverse-effect claims are asserted as common without support in the provided label text (headache, diarrhea, nausea), and an explanation/definition of retrograde ejaculation is not supported. Additionally, non-label content about pricing and generic substitution could mislead patients about expectations and product selection.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Noncompliant
Primary Issue
Large number of claims are not supported by the provided FDA label text, including generic substitution/bioequivalence and multiple adverse-effect/common-side-effect claims without label support.
Suggested Improvement
Restrict claims to label-supported content in the provided sections (e.g., indication, mechanism of action, and counseling statements such as postural symptoms and reduced/no semen). Remove unsupported pricing/patent/generic-manufacturer assertions and avoid asserting unsupported adverse effects as common or providing unsupported definitions.